GEN 1057
Alternative Names: GEN-1057Latest Information Update: 05 Jun 2026
At a glance
- Originator Genmab
- Class Antibodies; Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Fibroblast activation protein alpha agonists; T lymphocyte stimulants; TRAIL receptor 1 agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 20 May 2026 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (IV)
- 20 May 2026 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain (IV)
- 20 May 2026 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)